Fenofibrate for Patients With COVID-19 Requiring Hospitalization

Exclusion Criteria

• •Enrollment \> 72 hours of admission order or positive test result, whichever is later
• •Admission to the hospital with a respiratory SOFA \>=5 , Critical COVID-19, or Disease Severity Score \>5 (requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or all)
• •Known hypersensitivity to fenofibrate
• •For female subjects:
• •1. Pregenant, determined by a human chorionic gonadotropin (HCG) rapid detection kit or a blood test
• •2. Breastfeeding
• •3. Undergoing fertility treatments
• •Patient-reported history or electronic medical record history of kidney disease, defined as:
• •1. Any history of dialysis
• •2. History of chronic kidney disease stage IV
• •3. Estimated Glomerular Filtration Rate (eGFR) of \< 30ml/min/1.73 m2 at the time of enrollment
• •Acute pre-renal azotemia at the time of enrollment in the opinion of the investigator or bedside clinician
• •Most recent mean arterial blood pressure prior to enrollment \<65 mmHg
• •Patient-reported history or electronic medical record history of severe liver disease, defined as:
• •1. Cirrhosis
• •2. History of hepatitis B or C
• •3. Documented AST or ALT \> 10 times the upper limit of normal measured within 24 hours prior to enrollment
• •Patient-reported history or electronic medical record history of gallbladder disease
• •Potassium \>5.0 within 24 hours prior to enrollment unless a repeat value was \<=5.0
• •Treatment with coumarin anticoagulants (e.g., Warfarin), immunosuppressants (e.g. cisplatin), bile acid resins, or sulfonylurea.
• •Inability to obtain informed consent from participant or legally authorized representative
• •Enrollment in another blinded randomized clinical trial for COVID